Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $11.02 and traded as low as $10.30. Bayer Aktiengesellschaft shares last traded at $10.38, with a volume of 586,457 shares traded.

Wall Street Analysts Forecast Growth

BAYRY has been the topic of a number of research reports. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. Finally, Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. The firm has a fifty day simple moving average of $11.02 and a 200 day simple moving average of $11.40. The company has a market cap of $40.79 billion, a price-to-earnings ratio of -16.22, a P/E/G ratio of 3.35 and a beta of 0.59.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.The company had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.